Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HIMS Hims & Hers Health	$50.36 +0.7%	$53.82	$13.47 ▼ $72.98	$11.19B	2.02	24.17 million shs	22.04 million shs
RXRX Recursion Pharmaceuticals	$5.84 +5.8%	$4.92	$3.79 ▼ $12.36	$2.24B	0.91	17.09 million shs	52.85 million shs
SDGR Schrodinger	$21.45 -0.9%	$21.94	$16.60 ▼ $28.47	$1.59B	1.58	926,705 shs	962,275 shs
SMMT Summit Therapeutics	$26.20 -5.2%	$22.77	$8.71 ▼ $36.91	$20.52B	-1.01	3.76 million shs	3.00 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HIMS Hims & Hers Health	-3.32%	-0.39%	-15.45%	+83.66%	+127.47%
RXRX Recursion Pharmaceuticals	+2.41%	-3.50%	+14.05%	+0.36%	-33.89%
SDGR Schrodinger	+1.88%	-0.28%	+3.69%	-15.92%	-6.56%
SMMT Summit Therapeutics	-2.26%	+6.76%	+39.19%	+12.27%	+196.78%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
HIMS Hims & Hers Health	2.271 of 5 stars	2.0	2.0	2.4	3.3	1.9
RXRX Recursion Pharmaceuticals	1.1261 of 5 stars	2.2	2.0	1.6	1.7	0.6
SDGR Schrodinger	1.8305 of 5 stars	3.4	1.0	1.9	1.7	0.6
SMMT Summit Therapeutics	2.886 of 5 stars	4.4	3.0	1.5	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HIMS Hims & Hers Health	1.92	Reduce	$39.83	-20.90% Downside
RXRX Recursion Pharmaceuticals	2.33	Hold	$7.00	19.86% Upside
SDGR Schrodinger	2.75	Moderate Buy	$32.75	52.68% Upside
SMMT Summit Therapeutics	2.79	Moderate Buy	$34.67	32.32% Upside

Current Analyst Ratings Breakdown

Latest SMMT, SDGR, RXRX, and HIMS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/17/2025	HIMS Hims & Hers Health	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$45.00 ➝ $48.00
7/14/2025	SDGR Schrodinger	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$32.00 ➝ $30.00
7/8/2025	RXRX Recursion Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
7/3/2025	RXRX Recursion Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Equal Weight	$5.00
7/3/2025	SDGR Schrodinger	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Equal Weight	$28.00
7/1/2025	SMMT Summit Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$44.00
7/1/2025	SMMT Summit Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00
6/24/2025	HIMS Hims & Hers Health	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$45.00
6/23/2025	HIMS Hims & Hers Health	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell ➝ Sell
6/23/2025	HIMS Hims & Hers Health	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$30.00
6/23/2025	HIMS Hims & Hers Health	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Underperform ➝ Underperform

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HIMS Hims & Hers Health	$1.48B	7.63	$0.35 per share	141.95	$2.16 per share	23.31
RXRX Recursion Pharmaceuticals	$58.84M	40.35	N/A	N/A	$2.61 per share	2.24
SDGR Schrodinger	$207.54M	7.58	N/A	N/A	$5.78 per share	3.71
SMMT Summit Therapeutics	$700K	27,797.08	N/A	N/A	$0.53 per share	49.43

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HIMS Hims & Hers Health	$126.04M	$0.69	72.99	96.85	1.83	9.24%	22.75%	15.51%	8/4/2025 (Estimated)
RXRX Recursion Pharmaceuticals	-$463.66M	-$1.77	N/A	N/A	N/A	-961.32%	-74.70%	-54.02%	8/6/2025 (Estimated)
SDGR Schrodinger	-$187.12M	-$2.63	N/A	N/A	N/A	-83.39%	-44.74%	-26.29%	7/30/2025 (Estimated)
SMMT Summit Therapeutics	-$221.32M	-$0.34	N/A	N/A	N/A	N/A	-62.87%	-51.61%	8/5/2025 (Estimated)

Latest SMMT, SDGR, RXRX, and HIMS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	RXRX Recursion Pharmaceuticals	-$0.34	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	SMMT Summit Therapeutics	-$0.10	N/A	N/A	N/A	N/A	N/A
8/4/2025	Q2 2025	HIMS Hims & Hers Health	$0.17	N/A	N/A	N/A	$550.06 million	N/A
7/30/2025	Q2 2025	SDGR Schrodinger	-$0.83	N/A	N/A	N/A	$52.03 million	N/A
5/7/2025	Q1 2025	SDGR Schrodinger	-$0.81	-$0.82	-$0.01	-$0.82	$54.60 million	$59.55 million
5/5/2025	Q1 2025	HIMS Hims & Hers Health	$0.12	$0.20	+$0.08	$0.20	$535.21 million	$586.01 million
5/5/2025	Q1 2025	RXRX Recursion Pharmaceuticals	-$0.44	-$0.50	-$0.06	-$0.50	$18.12 million	$14.75 million
5/1/2025	Q1 2025	SMMT Summit Therapeutics	-$0.10	-$0.09	+$0.01	-$0.09	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
HIMS Hims & Hers Health	N/A	N/A	N/A	N/A	N/A
RXRX Recursion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SDGR Schrodinger	N/A	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HIMS Hims & Hers Health	N/A	1.59	1.32
RXRX Recursion Pharmaceuticals	0.02	4.11	4.11
SDGR Schrodinger	N/A	3.45	3.45
SMMT Summit Therapeutics	N/A	10.63	10.63

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HIMS Hims & Hers Health	63.52%
RXRX Recursion Pharmaceuticals	89.06%
SDGR Schrodinger	79.05%
SMMT Summit Therapeutics	4.61%

Insider Ownership

Company	Insider Ownership
HIMS Hims & Hers Health	13.71%
RXRX Recursion Pharmaceuticals	8.43%
SDGR Schrodinger	8.60%
SMMT Summit Therapeutics	84.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HIMS Hims & Hers Health	1,637	223.83 million	193.15 million	Optionable
RXRX Recursion Pharmaceuticals	400	406.49 million	372.23 million	Optionable
SDGR Schrodinger	790	73.38 million	67.07 million	Optionable
SMMT Summit Therapeutics	110	742.67 million	112.14 million	Optionable

SMMT, SDGR, RXRX, and HIMS Headlines

Recent News About These Companies

Principal Financial Group Inc. Has $4.75 Million Stock Holdings in Summit Therapeutics PLC (NASDAQ:SMMT)

July 18 at 3:15 AM | marketbeat.com

SMMT Investors Have Opportunity to Join Summit Therapeutics Inc. Fraud Investigation with the Schall Law Firm

July 17 at 10:53 AM | tmcnet.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT

July 17 at 10:00 AM | prnewswire.com

Summit Therapeutics (NASDAQ:SMMT) Shares Up 9% - Still a Buy?

July 16 at 1:00 PM | marketbeat.com

Florida Financial Advisors LLC Purchases Shares of 12,945 Summit Therapeutics PLC (NASDAQ:SMMT)

July 15 at 5:50 AM | marketbeat.com

SMMT Investors Have Opportunity to Join Summit Therapeutics Inc. Fraud Investigation with the Schall Law Firm

July 14, 2025 | businesswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT

July 12, 2025 | prnewswire.com

12,025 Shares in Summit Therapeutics PLC (NASDAQ:SMMT) Purchased by U.S. Capital Wealth Advisors LLC

July 12, 2025 | marketbeat.com

Summit Therapeutics Inc. (SMMT) Stock Price Today - WSJ

July 10, 2025 | wsj.com

Summit Therapeutics (NASDAQ:SMMT) Trading 7.6% Higher - Here's Why

July 9, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT

July 7, 2025 | prnewswire.com

Summit Therapeutics (NASDAQ:SMMT) Shares Gap Down - Here's Why

July 7, 2025 | marketbeat.com

SMMT Stock Gains on Rumored Licensing Talks With AstraZeneca

July 7, 2025 | zacks.com

Summit Therapeutics Inc. (SMMT) - Yahoo Finance

July 5, 2025 | finance.yahoo.com

2 Soaring Stocks With More Upside Potential to Buy and Hold

July 4, 2025 | fool.com

AstraZeneca in talks with Summit for over $15 billion license deal

July 4, 2025 | thepharmaletter.comT

Summit, AstraZeneca in talks over $15 billion partnership deal, Bloomberg News reports

July 3, 2025 | msn.com

Summit Therapeutics Shares Climb Amid Rumored $15B Deal Talks with AstraZeneca

July 3, 2025 | msn.com

Summit said to be in talks with Astra to license potential rival for Merck’s Keytruda

July 3, 2025 | msn.com

Why Summit Therapeutics Stock Soared 8% Higher Today

July 3, 2025 | fool.com

Summit Therapeutics (NASDAQ:SMMT) Stock Price Down 4.3% - Should You Sell?

July 3, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
Why Hims & Hers Stock Could Be a Multi-Bagger in the Making
By Gabriel Osorio-Mazilli | June 24, 2025
View Why Hims & Hers Stock Could Be a Multi-Bagger in the Making
Why Hims & Hers Is a Buy Below $35 After Its 16% Pullback
By Gabriel Osorio-Mazilli | July 3, 2025
View Why Hims & Hers Is a Buy Below $35 After Its 16% Pullback

SMMT, SDGR, RXRX, and HIMS Company Descriptions

Hims & Hers Health NYSE:HIMS

$50.36 +0.37 (+0.74%)

Closing price 03:59 PM Eastern

Extended Trading

$50.12 -0.24 (-0.48%)

As of 07:59 PM Eastern

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Recursion Pharmaceuticals NASDAQ:RXRX

$5.84 +0.32 (+5.80%)

Closing price 04:00 PM Eastern

Extended Trading

$5.88 +0.04 (+0.68%)

As of 07:59 PM Eastern

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Schrodinger NASDAQ:SDGR

$21.45 -0.20 (-0.92%)

Closing price 04:00 PM Eastern

Extended Trading

$21.74 +0.29 (+1.33%)

As of 07:57 PM Eastern

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

Summit Therapeutics NASDAQ:SMMT

$26.20 -1.43 (-5.18%)

Closing price 04:00 PM Eastern

Extended Trading

$26.36 +0.16 (+0.60%)

As of 07:58 PM Eastern

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time